arrow
B

Bahram Valamehr

fate therapeutics, inc.
H指数:28
被引数:3,326

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease

炎症小体抗性iPSC来源的髓源抑制细胞可减轻异种移植物抗宿主病

Blood
IF23.1
2025-07-250
PRE
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study

现成型诱导多能干细胞来源的自然杀伤细胞疗法在复发或难治性B细胞淋巴瘤中的应用:一项多中心、开放标签、I期研究

2025-07-010
PRE
iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors

iPSC来源的三模态T细胞(通过CAR、TCR和hnCD16模态工程化改造)能够克服异质性肿瘤中的抗原逃逸。

2025-06-190
OAAI
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

iPSC来源的CAR T细胞通过工程化改造克服多种实体瘤疗效障碍,实现对HER2的偏好性肿瘤靶向。

2025-06-040
PRE
A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape

一种新型的CD3ε融合受体允许在无TCR的同种异体CAR T细胞中使用T细胞连接器,以提高活性并防止抗原逃逸。

2025-05-280
PRE
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

同种免疫防御受体与粘附配体CD58的遗传剔除相结合是一种促进异基因细胞疗法功能持久性的综合方法,无需条件性化疗。

BLOOD
IF23.1
2024-11-050
PRE
CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma

CXCR4在改善BCMA重定向的car-nk细胞在多发性骨髓瘤中的疗效方面具有双重作用

2024-06-241
OAAI
High-avidity BCMA CAR and high- affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma
2024-03-220
PRE
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells (vol 6, pg 1284, 2022)
2024-02-120
OA
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors
MED
IF11.8
2023-07-0110
OA
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
2022-11-2938
OAAI
Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
2022-11-0120
OAAI
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells
2022-08-0847
OA